Active Clinical Studies

Protocol Title: Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer

Principal Investigator: Mohammad Memon, MD

Indication: Locally Advanced (inoperable) or metastatic HR+/HER2- breast cancer 

Study Description: The purpose of this study is to learn more about treatment with an experimental drug called capivasertib, added to a standard of care treatment fulvestrant + CDK4/6i (palbociclib or ribociclib) for patients with advanced breast cancer and to better understand the studied disease and associated health problems.
 

Protocol Title: A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Principal Investigator: Ahmed Jouan, MD

Indication: Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Study Description: The purpose of this study is to see if an experimental drug, called milvexian in addition to standard of care, is safe and useful in reducing the risk of future ischemic stroke in subjects after ischemic stroke or transient ischemic attack compared to placebo (tablet with no active drug) in addition to standard of care. An experimental drug is one that is not approved by the United States Food and Drug Administration (FDA). 
 

Protocol Title: CLINICAL BIOSPECIMEN COLLECTION TO SUPPORT BIOMARKER RESEARCH

Principal Investigator: Robert Johnson, MD

Indication: Various Cancers

Study Description: To collect the biological specimens to use towards biomarker development and other technologies or treatment for oncology patients. 

Protocol Title: A Multi-Center, Prospective, Single-Arm, Observational Study to Evaluate Real-World Outcomes for the Shape-Sensing Ion Endoluminal System

Principal Investigator: Elie Chbeir, MD

Indication: Patients undergoing a bronchoscopy to evaluate a lung nodule

Study Description: The purpose of this study is to collect data for research purposes for patients undergoing use the Ion Endoluminal System (referred to as “Ion”) to sample the tissue in your lung or to place a marker by the lesion (abnormal tissue growth) for future identification purposes. Ion is a robotic-assisted system that enables your doctor to perform a minimally invasive, bronchoscopic lung biopsy or localization procedure.
 

Protocol Title: A Phase 3, Randomized, Double Blind, Placebo Controlled Study of PF-06821497 (Mevrometostat) With Enzalutamide in Metastatic Castration Resistant Prostate Cancer (Nickname: MEVPRO-2)

Principal Investigator: David Lieber, MD

Indication: Metastatic Castration Resistant Prostate Cancer, prior to having received next-generation androgen deprivation therapy (e.g. apalutamide, enzalutamide, darolutamide and abiraterone)

Study Description: The purpose of this study is to explore whether a combination of the investigational drug mevrometostat and enzalutamide will work better than taking enzalutamide alone in the treatment of metastatic castration resistant prostate cancer (mCRPC).